AirSculpt Technologies (AIRS)
Market Price (8/20/2026): $2.815 | Market Cap: $199.3 MilSector: Health Care | Industry: Health Care Facilities
AirSculpt Technologies (AIRS)
Market Price (8/20/2026): $2.815Market Cap: $199.3 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Experience Economy & Premiumization. Themes include Aesthetic & Elective Procedures, and Premium Aesthetic Services. | Weak multi-year price returns2Y Excs Rtn is -66%, 3Y Excs Rtn is -135% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4.0% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 156x Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -8.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.5%, Rev Chg QQuarterly Revenue Change % is -2.5% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10% High stock price volatilityVol 12M is 128% Key risksAIRS key risks include [1] significant allegations concerning patient safety, Show more. |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Experience Economy & Premiumization. Themes include Aesthetic & Elective Procedures, and Premium Aesthetic Services. |
| Weak multi-year price returns2Y Excs Rtn is -66%, 3Y Excs Rtn is -135% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4.0% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 156x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -8.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.5%, Rev Chg QQuarterly Revenue Change % is -2.5% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10% |
| High stock price volatilityVol 12M is 128% |
| Key risksAIRS key risks include [1] significant allegations concerning patient safety, Show more. |
Qualitative Assessment
AI Analysis | Feedback
AirSculpt Technologies (AIRS) stock has gained about 5% since 4/30/2026 because of the following key factors:
1. Mixed Fiscal Q2 2026 Financial Results and Revised Outlook. AirSculpt Technologies reported mixed results for its fiscal second quarter ended June 30, 2026. Revenue declined 2.5% year-over-year to $42.9 million, missing the consensus estimate of $44.14 million. The company also reported a widened net loss of $1.1 million and a decrease in Adjusted EBITDA to $4.9 million from $5.8 million in the prior year. While there was positive 1% same-center case growth, the company reaffirmed its full-year 2026 revenue guidance at the lower end of its $151–$157 million range and reduced its Adjusted EBITDA outlook to $12–$14 million, citing an intentional additional $5 million investment in marketing. These results, announced on August 10, 2026, created downward pressure on the stock.
2. Challenging Consumer Environment. Management explicitly cited a "choppy consumer environment" that led to softening sales trends in June and continued into July. This broader macroeconomic headwind directly impacted the company's revenue performance and contributed to a cautious outlook for the fiscal third quarter, with comparable revenue (excluding London) expected to be down single digits.
Show more
AirSculpt Technologies (AIRS) stock has gained about 5% since 4/30/2026 because of the following key factors:
1. Mixed Fiscal Q2 2026 Financial Results and Revised Outlook. AirSculpt Technologies reported mixed results for its fiscal second quarter ended June 30, 2026. Revenue declined 2.5% year-over-year to $42.9 million, missing the consensus estimate of $44.14 million. The company also reported a widened net loss of $1.1 million and a decrease in Adjusted EBITDA to $4.9 million from $5.8 million in the prior year. While there was positive 1% same-center case growth, the company reaffirmed its full-year 2026 revenue guidance at the lower end of its $151–$157 million range and reduced its Adjusted EBITDA outlook to $12–$14 million, citing an intentional additional $5 million investment in marketing. These results, announced on August 10, 2026, created downward pressure on the stock.
2. Challenging Consumer Environment. Management explicitly cited a "choppy consumer environment" that led to softening sales trends in June and continued into July. This broader macroeconomic headwind directly impacted the company's revenue performance and contributed to a cautious outlook for the fiscal third quarter, with comparable revenue (excluding London) expected to be down single digits.
3. Increased Customer Acquisition Costs. AirSculpt Technologies experienced an increase in its Customer Acquisition Cost (CAC) to approximately $3,500 per case in fiscal Q2 2026, up from approximately $2,900 in the prior year quarter. This rise in the cost of acquiring new patients indicates a potential decrease in marketing efficiency and directly impacts the company's profitability, especially when coupled with the planned increase in overall marketing investment for the year.
4. Lack of Significant Positive Catalysts and Analyst Pessimism. Despite efforts such as debt reduction (gross debt fell by approximately $30 million since early 2025 to $44.2 million) and extending the term loan maturity to November 2027, the period lacked substantial positive catalysts to drive sustained stock appreciation. Following the Q2 earnings, analysts' average price targets dipped 28% to $4.50, reflecting increased pessimism and a "Hold" consensus rating, which contributed to the stock's inability to establish a clear upward trend.
Show less
Stock Movement Drivers
Fundamental Drivers
The 4.9% change in AIRS stock from 4/30/2026 to 8/19/2026 was primarily driven by a 22.2% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8192026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.68 | 2.81 | 4.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 152 | 151 | -0.7% |
| P/S Multiple | 1.1 | 1.3 | 22.2% |
| Shares Outstanding (Mil) | 61 | 71 | -13.5% |
| Cumulative Contribution | 4.9% |
Market Drivers
4/30/2026 to 8/19/2026| Return | Correlation | |
|---|---|---|
| AIRS | 4.9% | |
| Market (SPY) | 7.0% | 28.6% |
| Sector (XLV) | 20.3% | -12.9% |
Fundamental Drivers
The -5.4% change in AIRS stock from 1/31/2026 to 8/19/2026 was primarily driven by a -11.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 8192026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.97 | 2.81 | -5.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 158 | 151 | -4.3% |
| P/S Multiple | 1.2 | 1.3 | 12.1% |
| Shares Outstanding (Mil) | 62 | 71 | -11.8% |
| Cumulative Contribution | -5.4% |
Market Drivers
1/31/2026 to 8/19/2026| Return | Correlation | |
|---|---|---|
| AIRS | -5.4% | |
| Market (SPY) | 11.4% | 29.8% |
| Sector (XLV) | 14.0% | -1.7% |
Fundamental Drivers
The -57.5% change in AIRS stock from 7/31/2025 to 8/19/2026 was primarily driven by a -41.3% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8192026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.61 | 2.81 | -57.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 172 | 151 | -12.4% |
| P/S Multiple | 2.2 | 1.3 | -41.3% |
| Shares Outstanding (Mil) | 59 | 71 | -17.3% |
| Cumulative Contribution | -57.5% |
Market Drivers
7/31/2025 to 8/19/2026| Return | Correlation | |
|---|---|---|
| AIRS | -57.5% | |
| Market (SPY) | 22.7% | 29.2% |
| Sector (XLV) | 36.4% | 3.7% |
Fundamental Drivers
The -69.0% change in AIRS stock from 7/31/2023 to 8/19/2026 was primarily driven by a -54.9% change in the company's P/S Multiple.| (LTM values as of) | 7312023 | 8192026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.07 | 2.81 | -69.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 175 | 151 | -13.9% |
| P/S Multiple | 2.9 | 1.3 | -54.9% |
| Shares Outstanding (Mil) | 56 | 71 | -20.3% |
| Cumulative Contribution | -69.0% |
Market Drivers
7/31/2023 to 8/19/2026| Return | Correlation | |
|---|---|---|
| AIRS | -69.0% | |
| Market (SPY) | 73.9% | 33.0% |
| Sector (XLV) | 37.1% | 12.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AIRS Return | 8% | -78% | 102% | -31% | -62% | 36% | -82% |
| Peers Return | 55% | -80% | 20% | -20% | 54% | -6% | -55% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| AIRS Win Rate | 33% | 42% | 50% | 33% | 42% | 50% | |
| Peers Win Rate | 54% | 29% | 54% | 38% | 50% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| AIRS Max Drawdown | - | -84% | -48% | -59% | -83% | -53% | |
| Peers Max Drawdown | -32% | -86% | -61% | -57% | -48% | -41% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: APYX, BHC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/19/2026 (YTD)
How Low Can It Go
| Event | AIRS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -72.5% | -18.8% |
| % Gain to Breakeven | 263.5% | 23.1% |
| Time to Breakeven | 92 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -13.6% | -7.8% |
| % Gain to Breakeven | 15.7% | 8.5% |
| Time to Breakeven | 4 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -42.2% | -9.5% |
| % Gain to Breakeven | 72.9% | 10.5% |
| Time to Breakeven | 357 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -34.8% | -6.7% |
| % Gain to Breakeven | 53.4% | 7.1% |
| Time to Breakeven | 66 days | 31 days |
In The Past
AirSculpt Technologies's stock fell -72.5% during the 2025 US Tariff Shock. Such a loss loss requires a 263.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AIRS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -72.5% | -18.8% |
| % Gain to Breakeven | 263.5% | 23.1% |
| Time to Breakeven | 92 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -42.2% | -9.5% |
| % Gain to Breakeven | 72.9% | 10.5% |
| Time to Breakeven | 357 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -34.8% | -6.7% |
| % Gain to Breakeven | 53.4% | 7.1% |
| Time to Breakeven | 66 days | 31 days |
In The Past
AirSculpt Technologies's stock fell -72.5% during the 2025 US Tariff Shock. Such a loss loss requires a 263.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AirSculpt Technologies (AIRS)
AirSculpt Technologies, Inc. (AIRS) is a company focused on providing specialized body contouring procedure services across the United States. Operating as a holding company for EBS Intermediate Parent LLC, AirSculpt's core business revolves around its proprietary "AirSculpt procedure," a minimally invasive technique designed to remove unwanted fat from various areas of the body. This signature procedure forms the foundation of its offerings, catering to individuals seeking advanced cosmetic improvements.
In addition to fat removal, AirSculpt Technologies expands its services to include fat transfer procedures, where a patient's own fat cells are utilized to enhance other body parts, such as the breasts, buttocks, or hips. Specific popular procedures include the Power BBL (Brazilian butt lift), Up a Cup (breast enhancement), and Hip Flip (hourglass contouring). With a network of 19 centers across 15 states, AirSculpt Technologies serves a primary market of consumers throughout the U.S. seeking personalized aesthetic body sculpting and enhancement solutions.
AI Analysis | Feedback
Here are a few analogies for AirSculpt Technologies (AIRS):
- Like Ideal Image for body contouring.
- Like LasikPlus for cosmetic fat removal procedures.
- Like Drybar for specialized cosmetic fat removal services.
AI Analysis | Feedback
- AirSculpt Procedure: A minimally invasive custom body contouring procedure that removes unwanted fat.
- Power BBL: A Brazilian butt lift procedure that utilizes the patient's own fat cells for enhancement.
- Up a Cup: A breast enhancement procedure that uses the patient's own fat cells.
- Hip Flip: An hourglass contouring procedure that sculpts the hips using fat transfer.
AI Analysis | Feedback
AirSculpt Technologies (AIRS) sells primarily to individuals rather than other companies. Based on the services described, its customers are individuals seeking cosmetic body contouring procedures. The categories of customers it serves can be described as follows:
- Individuals seeking targeted fat reduction: These customers are looking to remove unwanted fat from specific areas of their body using minimally invasive procedures like AirSculpt.
- Individuals seeking natural body augmentation and enhancement: This category includes customers who desire to enhance or reshape specific body parts, such as breasts, buttocks, or hips, by utilizing their own fat cells through procedures like the Power BBL, Up a Cup, or Hip Flip.
- Individuals seeking overall body sculpting and aesthetic improvement: These customers are generally looking for a more comprehensive transformation of their physique, often combining fat removal and transfer techniques to achieve a desired contour and improve their overall body image and confidence.
AI Analysis | Feedback
AI Analysis | Feedback
Yogi Jashnani, Chief Executive Officer
Mr. Jashnani has served as Chief Executive Officer since January 7, 2025. He has over 20 years of experience in the aesthetics, retail, and finance industries. Prior to joining AirSculpt Technologies, he was Chief Revenue Officer for Sky Zone. From 2019 through 2023, he served as Chief Commercial Officer of Ideal Image. Earlier, from fiscal 2017 through 2019, he was SVP, Marketing, Insights and Analytics of Advance Auto Parts, and before that, Vice President at Capital One.
Michael Arthur, Chief Financial Officer
Mr. Arthur oversees all financial strategy and operations for AirSculpt Technologies, including accounting, FP&A, treasury, and capital markets. He previously served as CFO of Inspirato Incorporated, where he also held senior finance leadership roles including Senior Vice President of Finance and Vice President of FP&A and Treasury. Earlier in his career, Mr. Arthur held finance and strategy roles at CSC Generation and VF Corporation and began his career in PwC's Financial Services practice.
Brian Stetter, Chief Digital Officer
Mr. Stetter has served as Chief Digital Officer for AirSculpt since October 2024, leading the marketing and digital technology teams. He has over 20 years of experience in marketing across multiple industries. Most recently, he was Chief Marketing Officer for Walker Advertising and previously served as VP, Performance Marketing for Ideal Image.
Nicole Soler, Chief Sales Officer
Ms. Soler drives sales strategy, revenue optimization, and client engagement at AirSculpt Technologies, leading large, cross-functional teams. She brings over 12 years of executive leadership experience and 14 years in consultative and value-based selling, during which she has built, scaled, and optimized high-performing sales organizations across various industries.
AI Analysis | Feedback
Here are the key risks to AirSculpt Technologies (AIRS):
- Patient Safety, Malpractice, and Reputational/Regulatory Risks: AirSculpt Technologies faces significant risks related to patient safety, potential medical malpractice claims, and regulatory scrutiny. The nature of cosmetic procedures inherently carries a risk of adverse outcomes for patients, which can lead to lawsuits and litigation from unsatisfied clients. There have been specific allegations of severe injuries, including patient death and permanent disfigurement, as well as claims of doctors with questionable credentials, revoked licenses, and misleading advertising practices such as employees posing as patients or undisclosed paid influencer reviews. Furthermore, the medical aesthetics industry operates within a complex and increasingly scrutinized regulatory environment, encompassing healthcare laws, facility licensing, medical oversight, and restrictions on advertising claims. Non-compliance with these regulations can expose the company to significant legal and financial risks, severely impacting its brand and operational viability.
- Revenue Softness, Challenges in Executing Growth Strategies, and Market Demand Volatility: The company has experienced ongoing revenue softness, a lowered 2025 outlook, and significant misses in recent quarterly earnings forecasts. This is attributed, in part, to consumer hesitancy in making higher-consideration purchases and uncertain demand for new services, including those targeting GLP-1 users. AirSculpt Technologies' ability to reverse these trends depends heavily on the effective execution of its cost-saving initiatives, operational consolidation, and new revenue growth strategies. Factors like inflation and broader economic pressures can also lead consumers to postpone discretionary spending, further impacting procedure volume and overall revenue. The company's negative operating margin and free cash flow, along with tight liquidity and at-risk interest coverage, highlight the financial challenges associated with these revenue and growth issues.
- Intense Competition and Lack of Strong Differentiated Advantage: The body contouring and fat reduction market is highly competitive, with numerous offerings from various companies, including both surgical and non-surgical methods. AirSculpt Technologies' business model is described as having a "low tech nature" with no patent protection for its devices, meaning its competitive advantage largely relies on the strength of its brand rather than proprietary technology. This competitive landscape makes it challenging for AirSculpt to maintain market share, achieve scalable growth, and defend against new entrants or evolving aesthetic technologies.
AI Analysis | Feedback
AI Analysis | Feedback
AirSculpt Technologies (symbol: AIRS) operates in the aesthetic body contouring market, focusing on minimally invasive fat removal and fat transfer procedures in the United States. The addressable markets for their main products and services are significant.
Fat Removal Procedures (Custom Body Contouring / Minimally Invasive Fat Reduction)
The market for non-invasive fat reduction in the U.S. is valued at approximately USD 1.8 billion. This market, which aligns with AirSculpt's minimally invasive fat removal procedures, is projected to reach USD 1.83 billion in North America by 2033, growing from USD 0.65 billion in 2025 at a compound annual growth rate (CAGR) of 13.87% from 2025 to 2033. North America is a dominant region in the non-invasive fat reduction market.
Fat Transfer Procedures (including Power BBL, Up a Cup, Hip Flip)
For fat transfer procedures, often referred to as autologous fat grafting, the global market was valued at US$ 202.4 million in 2024 and is expected to reach US$ 375.3 million by 2033, growing at a CAGR of 7.1%. North America is the leading regional market for autologous fat grafting in terms of revenue share.
Specifically for buttock augmentation, which includes procedures like the Brazilian Butt Lift (BBL) offered by AirSculpt, the global market is expected to reach USD 6.6 billion by 2028, growing at a CAGR of 22.0% from 2021 to 2028. North America dominates the buttock augmentation market. In the U.S., a significant number of buttock augmentation procedures are performed annually; for instance, the American Society of Aesthetic Plastic Surgeons (ASAPS) reported 61,387 buttock augmentations in 2021.
AI Analysis | Feedback
AirSculpt Technologies (symbol: AIRS) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
- Expansion to New Markets and Centers: AirSculpt Technologies continues to open new body contouring centers. For example, the company opened its 32nd location in White Plains, NY, in December 2024 and its 30th location in Deerfield, IL, in September 2024. While the London center was closed in Q3 2025, the company stated its intention to focus resources on North American locations where it sees significant opportunity. This ongoing domestic expansion is a key driver.
- Launch and Growth of New Products and Services: The company is introducing and expanding specialized procedures. This includes the AirSculpt+ skin tightening procedure, which combines fat removal with Renuvion® technology and is being offered in new and existing centers. Additionally, AirSculpt Lift, a minimally invasive facial fat transfer procedure, was added to the Scottsdale location in March 2024 and has been popular in other markets.
- Development of Offerings for GLP-1 Users: AirSculpt Technologies began piloting new services in Q2 2025, specifically focusing on skin tightening that addresses the skin laxity associated with the use of GLP-1 medications. The CEO highlighted this as a "broader market opportunity ahead driven by the structural shift in the aesthetics space due to GLP-1 use."
- Enhanced Go-to-Market Processes and Customer Experience Initiatives: The company is implementing "transformation initiatives" and "elevated go-to-market processes" aimed at improving customer acquisition and experience. These strategies include optimizing marketing efforts, refining sales processes, and expanding financing options to provide greater flexibility for consumers, which are expected to accelerate comparable sales improvement.
AI Analysis | Feedback
Share Issuance
- AirSculpt Technologies completed an Initial Public Offering (IPO) in October 2021, issuing 2,173,913 shares as part of a larger offering of 7,000,000 shares at $11.00 per share.
- In June 2025, the company launched an underwritten public offering of 3,160,000 shares of its common stock.
- This June 2025 offering was priced at $3.80 per share, generating $12.0 million in proceeds for the company before expenses.
Inbound Investments
- Vesey Street Capital Partners, a significant stockholder, indicated interest in purchasing up to $4 million in shares during the June 2025 public offering.
- As of March 2026, institutional investors and hedge funds held approximately 91.54% of the company's stock.
- Several institutional investors, including Aristides Capital LLC, Virtu Financial LLC, XTX Topco Ltd, and Caitong International Asset Management Co. Ltd, bought new stakes or increased their holdings in AirSculpt Technologies during the fourth quarter of 2025.
Capital Expenditures
- AirSculpt Technologies reported $180K in capital expenditures in Q3 2025, representing a 32.1% decrease from the previous quarter.
- In Q3 2025, capital expenditures totaled $14.0M, which largely consumed the $11.3M generated from operating cash flow, resulting in a negative free cash flow of -$2.7M.
Peer Outperformance in Health Care Facilities
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 8.4% | 80.2% | 137.8% | CAH 410% · MCK 337% · COR 180% |
| Health Care Services | 20 | 19.9% | 44.4% | 9.4% | HIMS 337% · RDNT 147% · DGX 75% |
| Managed Health Care | 8 | 32.1% | -4.0% | -0.3% | OSCR 138% · HQY 65% · ELV 13% |
| Health Care Facilities ← | 24 | 8.8% | -3.9% | -15.3% | THC 270% · NHC 261% · ENSG 126% |
| Health Care Equipment | 51 | -1.1% | -6.1% | -17.6% | POCI 11000% · UFPT 381% · GKOS 287% |
| Health Care Supplies | 12 | 38.2% | -12.0% | -25.7% | LNTH 302% · HAE 82% · MMSI 33% |
| Pharmaceuticals | 63 | 7.3% | 0.7% | -29.1% | LQDA 2808% · INDV 1373% · ETON 1294% |
| Life Sciences Tools & Services | 108 | -0.5% | -31.3% | -70.9% | SNWV 1990% · ELMD 257% · MEDP 241% |
| Health Care Technology | 20 | -23.4% | -53.0% | -73.9% | SPOK 118% · HSTM -3% · VEEV -22% |
| Biotechnology | 366 | 17.1% | -23.9% | -76.7% | BRTX 106550% · DNTH 1652% · CELZ 1500% |
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.15 |
| Mkt Cap | 0.2 |
| Rev LTM | 151 |
| Op Inc LTM | -4 |
| FCF LTM | 1 |
| FCF 3Y Avg | 1 |
| CFO LTM | 1 |
| CFO 3Y Avg | 8 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.1% |
| Rev Chg 3Y Avg | 7.9% |
| Rev Chg Q | 12.7% |
| QoQ Delta Rev Chg LTM | 3.1% |
| Op Inc Chg LTM | 46.4% |
| Op Inc Chg 3Y Avg | 36.8% |
| Op Mgn LTM | -4.0% |
| Op Mgn 3Y Avg | -1.5% |
| QoQ Delta Op Mgn LTM | 1.6% |
| CFO/Rev LTM | 0.8% |
| CFO/Rev 3Y Avg | 4.5% |
| FCF/Rev LTM | 0.5% |
| FCF/Rev 3Y Avg | 0.6% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Direct medical procedure services | 152 | 180 | 196 | 169 | 133 |
| Total | 152 | 180 | 196 | 169 | 133 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Direct medical procedure services | -12 | -2 | 10 | -5 |
| Total | -12 | -2 | 10 | -5 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Direct medical procedure services | -12 | -8 | -4 | -15 |
| Total | -12 | -8 | -4 | -15 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Direct medical procedure services | 187 | 210 | 205 | 201 |
| Total | 187 | 210 | 205 | 201 |
Price Behavior
| Market Price | $2.81 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 10/29/2021 | |
| Distance from 52W High | -75.9% | |
| 50 Days | 200 Days | |
| DMA Price | $4.47 | $3.60 |
| DMA Trend | down | down |
| Distance from DMA | -37.1% | -22.0% |
| 3M | 1YR | |
| Volatility | 120.0% | 128.3% |
| Downside Capture | 557.45 | 441.23 |
| Upside Capture | 198.10 | 256.74 |
| Correlation (SPY) | 28.7% | 28.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.66 | 2.26 | 2.57 | 2.79 | 2.83 | 2.16 |
| Up Beta | 6.08 | 2.18 | 0.47 | 1.47 | 3.34 | 2.10 |
| Down Beta | 3.34 | 4.14 | 3.24 | 2.45 | 2.14 | 1.54 |
| Up Capture | 205% | 129% | 588% | 723% | 492% | 2070% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 8 | 13 | 28 | 56 | 118 | 349 |
| Down Capture | 96% | 174% | 164% | 210% | 180% | 112% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 12 | 27 | 32 | 67 | 129 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIRS | |
|---|---|---|---|---|
| AIRS | -55.7% | 128.0% | 0.01 | - |
| Sector ETF (XLV) | 31.1% | 15.8% | 1.51 | 3.7% |
| Equity (SPY) | 20.7% | 12.8% | 1.19 | 28.6% |
| Gold (GLD) | 35.0% | 28.8% | 1.04 | 12.6% |
| Commodities (DBC) | 41.4% | 20.2% | 1.60 | -1.4% |
| Real Estate (VNQ) | 15.3% | 13.9% | 0.78 | 8.8% |
| Bitcoin (BTCUSD) | -44.7% | 42.7% | -1.27 | 27.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIRS | |
|---|---|---|---|---|
| AIRS | -29.3% | 96.1% | 0.07 | - |
| Sector ETF (XLV) | 7.6% | 15.1% | 0.31 | 21.0% |
| Equity (SPY) | 13.1% | 17.2% | 0.59 | 37.2% |
| Gold (GLD) | 20.4% | 18.6% | 0.89 | 6.3% |
| Commodities (DBC) | 9.8% | 19.6% | 0.39 | 3.9% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.03 | 27.0% |
| Bitcoin (BTCUSD) | 7.2% | 52.6% | 0.32 | 24.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIRS | |
|---|---|---|---|---|
| AIRS | -15.9% | 96.1% | 0.07 | - |
| Sector ETF (XLV) | 10.8% | 16.7% | 0.53 | 21.0% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 37.2% |
| Gold (GLD) | 12.5% | 16.2% | 0.63 | 6.3% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | 3.9% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 27.0% |
| Bitcoin (BTCUSD) | 60.0% | 66.0% | 1.00 | 24.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/19/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/10/2026 | -45.1% | -31.5% | |
| 5/8/2026 | 11.6% | 37.0% | 45.4% |
| 3/16/2026 | 51.6% | 43.2% | 41.6% |
| 11/7/2025 | -41.7% | -45.5% | -71.7% |
| 8/1/2025 | -10.5% | -6.2% | -2.4% |
| 5/2/2025 | 33.6% | 25.2% | 97.3% |
| 3/14/2025 | -2.7% | -4.4% | -38.1% |
| 1/13/2025 | -19.9% | -10.9% | -9.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 8 | 7 |
| # Negative | 11 | 13 | 13 |
| Median Positive | 16.1% | 26.7% | 45.4% |
| Median Negative | -12.1% | -6.6% | -13.4% |
| Max Positive | 51.6% | 64.0% | 97.3% |
| Max Negative | -45.1% | -45.5% | -71.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/10/2026 | -45.1% | -31.5% | |
| 5/8/2026 | 11.6% | 37.0% | 45.4% |
| 3/16/2026 | 51.6% | 43.2% | 41.6% |
| 11/7/2025 | -41.7% | -45.5% | -71.7% |
| 8/1/2025 | -10.5% | -6.2% | -2.4% |
| 5/2/2025 | 33.6% | 25.2% | 97.3% |
| 3/14/2025 | -2.7% | -4.4% | -38.1% |
| 1/13/2025 | -19.9% | -10.9% | -9.7% |
| 11/8/2024 | 20.7% | -3.2% | -13.4% |
| 8/9/2024 | 1.0% | -1.3% | -5.8% |
| 5/10/2024 | -12.1% | -19.9% | -23.0% |
| 2/27/2024 | -2.1% | -5.5% | -4.9% |
| 10/5/2023 | -2.3% | -0.2% | -14.8% |
| 7/11/2023 | 10.1% | 9.9% | 1.2% |
| 5/12/2023 | 37.4% | 64.0% | 63.4% |
| 3/10/2023 | -22.0% | -14.5% | -14.2% |
| 11/10/2022 | -30.7% | -30.2% | -33.4% |
| 8/12/2022 | 26.1% | 21.1% | 7.1% |
| 5/13/2022 | 2.8% | -6.6% | -4.5% |
| 3/11/2022 | -0.1% | 2.5% | -1.1% |
| 12/3/2021 | 2.5% | 28.2% | 52.3% |
| SUMMARY STATS | |||
| # Positive | 10 | 8 | 7 |
| # Negative | 11 | 13 | 13 |
| Median Positive | 16.1% | 26.7% | 45.4% |
| Median Negative | -12.1% | -6.6% | -13.4% |
| Max Positive | 51.6% | 64.0% | 97.3% |
| Max Negative | -45.1% | -45.5% | -71.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/10/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/10/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/11/2022 | 10-K |
| 09/30/2021 | 12/03/2021 | 10-Q |
| 06/30/2021 | 10/29/2021 | 424B4 |
Recent Forward Guidance
Updated 8/11/2026Latest: Q2 2026 Earnings Reported 8/10/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 151.00 Mil | 154.00 Mil | 157.00 Mil | 0 | Affirmed | Guidance: 154.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | 12.00 Mil | 13.00 Mil | 14.00 Mil | -18.8% | Lowered | Guidance: 16.00 Mil for 2026 | |
Prior: Q1 2026 Earnings Reported 5/8/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 151.00 Mil | 154.00 Mil | 157.00 Mil | ||||
| 2026 Adjusted EBITDA | 15.00 Mil | 16.00 Mil | 17.00 Mil | ||||
Q4 2025 Earnings Reported 3/16/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | 38.50 Mil | 39.00 Mil | 39.50 Mil | ||||
Q3 2025 Earnings Reported 11/7/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 153.00 Mil | -7.3% | Lowered | Guidance: 165.00 Mil for 2025 | |||
| 2025 Adjusted EBITDA | 16.00 Mil | -5.9% | Lowered | Guidance: 17.00 Mil for 2025 | |||
Insider Activity
Updated 5/20/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chernett, Jorey | Direct | Buy | 4202026 | 2.54 | 40,000 | 101,600 | 17,916,553 | Form | |
| 2 | Chernett, Jorey | Direct | Buy | 4152026 | 2.60 | 20,000 | 52,000 | 18,235,779 | Form | |
| 3 | Chernett, Jorey | Direct | Buy | 4082026 | 2.93 | 60,000 | 175,800 | 20,491,720 | Form | |
| 4 | Chernett, Jorey | Direct | Buy | 4062026 | 2.82 | 90,000 | 253,800 | 19,553,206 | Form | |
| 5 | Chernett, Jorey | Direct | Buy | 3252026 | 2.91 | 50,000 | 145,500 | 19,915,345 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chernett, Jorey | Direct | Buy | 4202026 | 2.54 | 40,000 | 101,600 | 17,916,553 | Form | |
| 2 | Chernett, Jorey | Direct | Buy | 4152026 | 2.60 | 20,000 | 52,000 | 18,235,779 | Form | |
| 3 | Chernett, Jorey | Direct | Buy | 4082026 | 2.93 | 60,000 | 175,800 | 20,491,720 | Form | |
| 4 | Chernett, Jorey | Direct | Buy | 4062026 | 2.82 | 90,000 | 253,800 | 19,553,206 | Form | |
| 5 | Chernett, Jorey | Direct | Buy | 3252026 | 2.91 | 50,000 | 145,500 | 19,915,345 | Form | |
| 6 | Chernett, Jorey | Direct | Buy | 3232026 | 2.77 | 40,000 | 110,800 | 18,818,718 | Form | |
| 7 | Chernett, Jorey | Direct | Buy | 3202026 | 2.64 | 77,702 | 205,133 | 17,829,929 | Form | |
| 8 | Chernett, Jorey | Direct | Buy | 3182026 | 2.56 | 83,000 | 212,480 | 17,090,711 | Form | |
| 9 | Chernett, Jorey | Direct | Buy | 3162026 | 2.43 | 105,848 | 257,211 | 16,018,703 | Form | |
| 10 | Chernett, Jorey | Direct | Buy | 3112026 | 2.15 | 88,000 | 189,200 | 13,945,354 | Form | |
| 11 | Chernett, Jorey | Direct | Buy | 3092026 | 2.00 | 45,600 | 91,200 | 12,796,422 | Form | |
| 12 | Chernett, Jorey | Direct | Buy | 3042026 | 1.87 | 30,000 | 56,100 | 11,879,383 | Form | |
| 13 | Chernett, Jorey | Direct | Buy | 3042026 | 1.71 | 80,000 | 136,800 | 10,811,665 | Form | |
| 14 | Feinstein, Adam T | VSCP EBS Aggregator, L.P. | Buy | 6112025 | 4.00 | 462,957 | 1,851,828 | 56,155,276 | Form | |
| 15 | Feinstein, Adam T | Vesey Street Capital Partners Healthcare Fund-A, LP | Buy | 6112025 | 4.00 | 149,185 | 596,740 | 18,095,596 | Form | |
| 16 | Feinstein, Adam T | EBS Aggregator Blocker Holdings, LLC | Buy | 6112025 | 4.00 | 387,858 | 1,551,432 | 47,045,848 | Form | |
| 17 | Rollins, Aaron | Executive Chairman | Direct | Buy | 5202025 | 3.60 | 2,118 | 7,629 | 54,556,032 | Form |
| 18 | Jashnani, Yogesh | Chief Executive Officer | Direct | Buy | 5072025 | 2.65 | 7,000 | 18,532 | 1,230,767 | Form |
AirSculpt Technologies — Investor Video Playlist
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.